Business Context and Reporting Period
This Form 8-K, filed on August 1, 2018, reports the completion of an asset acquisition by Nutriband Inc. The company acquired 100% of the equity interests of 4P Therapeutics, LLC, a Delaware limited liability company focused on developing transdermal drug delivery technologies. The principal product under development is the Defent™ fentanyl transdermal system, designed to deter abuse and misuse of fentanyl patches. The transaction closed on August 1, 2018, pursuant to an agreement dated April 5, 2018.
Key Financial Metrics
Acquisition Details
- Total Purchase Price: $2,250,000
- Payment Structure: $400,000 in cash and 250,000 shares of Nutriband common stock (valued at $1,850,000).
- Assets Acquired: Fixed assets and intellectual property (including customer lists and IP valued at $1,500,000).
4P Therapeutics Historical Performance (Acquired Entity)
| Metric | Year Ended Dec 31, 2017 | Six Months Ended June 30, 2018 |
|---|---|---|
| Revenue | $568,005 | $331,864 |
| Net Income (Loss) | $45,412 | $22,979 |
| Total Assets | $218,278 | $251,659 |
| Total Liabilities | $178,730 | $189,132 |
| Cash and Equivalents | $25,114 | $106,598 |
Note: 4P Therapeutics had outstanding debt of $88,750 as of June 30, 2018, which was repaid in full in August 2018 as part of the transaction.
Pro Forma Combined Results (Nutriband + 4P)
The filing includes unaudited pro forma financial information assuming the acquisition occurred on February 1, 2017 (for the year ended Jan 31, 2018) and February 1, 2018 (for the six months ended July 31, 2018).
- Pro Forma Net Loss (Six Months Ended July 31, 2018): $(2,421,391)
- Pro Forma Net Loss (Year Ended Jan 31, 2018): $(2,861,534)
- Pro Forma Loss Per Share (Six Months): $(0.11)
- Pro Forma Loss Per Share (Year): $(0.15)
Material Changes
- Balance Sheet Impact: The acquisition added $2,150,000 in intangible assets (customer list and intellectual property) and $100,000 in fixed assets to Nutriband's balance sheet.
- Debt Resolution: All debt obligations of 4P Therapeutics, totaling approximately $90,000 (including related party advances), were paid in full in August 2018.
- Revenue Recognition: 4P Therapeutics adopted ASC 606 (new revenue standards) effective January 1, 2018. The company does not expect this to have a material impact on its financial statements.
Outlook, Risks, and Contingencies
- Development Stage: 4P Therapeutics is a development-stage company with no FDA premarketing approval for its products. Future success depends on clinical trials and regulatory approval.
- Valuation Risk: The purchase price allocation is preliminary. The final allocation of the $2,250,000 purchase price to specific assets (IP, customer lists, fixed assets) may differ materially once detailed valuations are completed.
- Pro Forma Limitations: The pro forma financial statements are for informational purposes only and do not reflect the actual results of operations or future financial position of the combined company.
- Customer Concentration: For the year ended December 31, 2017, 4P's two largest customers represented approximately 83% of total sales (66% and 17%).
Investor Verification Checklist
- Verify the final purchase price allocation and the specific valuation of the acquired intellectual property and customer lists.
- Review the status of the Defent™ fentanyl transdermal system development and any upcoming regulatory milestones.
- Confirm the integration of 4P Therapeutics' operations and the realization of synergies.
- Monitor the impact of the acquisition on Nutriband's cash flow and liquidity, given the cash portion of the purchase price.
- Assess the concentration risk associated with 4P's top two customers and the stability of those relationships post-acquisition.